Implanted renal replacement for end-stage renal disease

S. Roy, K. G. Goldman, R. E. Marchant, Andrew Zydney, D. L. Brown, A. J. Fleischman, A. T. Conlisk, T. A. Desai, S. Duffy, H. D. Humes, W. H. Fissell

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The nearly 400000 American patients on dialysis suffer high cardiovascular and infectious mortality, but there is now evidence that this morbid phenotype can be rescued by intensive dialytic therapy. Self-care dialysis at home is limited by patient fears about skill and safety. An implanted artificial kidney would provide the benefits of intensive therapy while avoiding the focal points of patient concern. Hollow fiber polymer membranes and dialytic waste removal are lifesaving innovations but are difficult to adapt to implantable therapies. Biomimetic membranes and living cells can replicate the native kidney's strategy for waste removal. Three key technology developments are necessary for implementation of an implantable artificial kidney: high efficiency ultrafiltration membranes, control of blood-materials interactions such as thrombosis and fouling, and stable differentiated function of renal proximal tubule cells in an engineered construct. There has been significant progress in demonstrating proof-of-concept experiments in each key technology area.

Original languageEnglish (US)
Pages (from-to)155-166
Number of pages12
JournalPanminerva Medica
Volume53
Issue number3
StatePublished - Sep 1 2011

Fingerprint

Chronic Kidney Failure
Artificial Kidneys
Kidney
Dialysis
Biomimetics
Proximal Kidney Tubule
Membranes
Ultrafiltration
Self Care
Fear
Polymers
Thrombosis
Therapeutics
Cell Membrane
Technology
Phenotype
Safety
Mortality
Industrial Development

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Roy, S., Goldman, K. G., Marchant, R. E., Zydney, A., Brown, D. L., Fleischman, A. J., ... Fissell, W. H. (2011). Implanted renal replacement for end-stage renal disease. Panminerva Medica, 53(3), 155-166.
Roy, S. ; Goldman, K. G. ; Marchant, R. E. ; Zydney, Andrew ; Brown, D. L. ; Fleischman, A. J. ; Conlisk, A. T. ; Desai, T. A. ; Duffy, S. ; Humes, H. D. ; Fissell, W. H. / Implanted renal replacement for end-stage renal disease. In: Panminerva Medica. 2011 ; Vol. 53, No. 3. pp. 155-166.
@article{e7ffbb40b9d3452a83908ee481ce46ef,
title = "Implanted renal replacement for end-stage renal disease",
abstract = "The nearly 400000 American patients on dialysis suffer high cardiovascular and infectious mortality, but there is now evidence that this morbid phenotype can be rescued by intensive dialytic therapy. Self-care dialysis at home is limited by patient fears about skill and safety. An implanted artificial kidney would provide the benefits of intensive therapy while avoiding the focal points of patient concern. Hollow fiber polymer membranes and dialytic waste removal are lifesaving innovations but are difficult to adapt to implantable therapies. Biomimetic membranes and living cells can replicate the native kidney's strategy for waste removal. Three key technology developments are necessary for implementation of an implantable artificial kidney: high efficiency ultrafiltration membranes, control of blood-materials interactions such as thrombosis and fouling, and stable differentiated function of renal proximal tubule cells in an engineered construct. There has been significant progress in demonstrating proof-of-concept experiments in each key technology area.",
author = "S. Roy and Goldman, {K. G.} and Marchant, {R. E.} and Andrew Zydney and Brown, {D. L.} and Fleischman, {A. J.} and Conlisk, {A. T.} and Desai, {T. A.} and S. Duffy and Humes, {H. D.} and Fissell, {W. H.}",
year = "2011",
month = "9",
day = "1",
language = "English (US)",
volume = "53",
pages = "155--166",
journal = "Panminerva Medica",
issn = "0031-0808",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

Roy, S, Goldman, KG, Marchant, RE, Zydney, A, Brown, DL, Fleischman, AJ, Conlisk, AT, Desai, TA, Duffy, S, Humes, HD & Fissell, WH 2011, 'Implanted renal replacement for end-stage renal disease', Panminerva Medica, vol. 53, no. 3, pp. 155-166.

Implanted renal replacement for end-stage renal disease. / Roy, S.; Goldman, K. G.; Marchant, R. E.; Zydney, Andrew; Brown, D. L.; Fleischman, A. J.; Conlisk, A. T.; Desai, T. A.; Duffy, S.; Humes, H. D.; Fissell, W. H.

In: Panminerva Medica, Vol. 53, No. 3, 01.09.2011, p. 155-166.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Implanted renal replacement for end-stage renal disease

AU - Roy, S.

AU - Goldman, K. G.

AU - Marchant, R. E.

AU - Zydney, Andrew

AU - Brown, D. L.

AU - Fleischman, A. J.

AU - Conlisk, A. T.

AU - Desai, T. A.

AU - Duffy, S.

AU - Humes, H. D.

AU - Fissell, W. H.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - The nearly 400000 American patients on dialysis suffer high cardiovascular and infectious mortality, but there is now evidence that this morbid phenotype can be rescued by intensive dialytic therapy. Self-care dialysis at home is limited by patient fears about skill and safety. An implanted artificial kidney would provide the benefits of intensive therapy while avoiding the focal points of patient concern. Hollow fiber polymer membranes and dialytic waste removal are lifesaving innovations but are difficult to adapt to implantable therapies. Biomimetic membranes and living cells can replicate the native kidney's strategy for waste removal. Three key technology developments are necessary for implementation of an implantable artificial kidney: high efficiency ultrafiltration membranes, control of blood-materials interactions such as thrombosis and fouling, and stable differentiated function of renal proximal tubule cells in an engineered construct. There has been significant progress in demonstrating proof-of-concept experiments in each key technology area.

AB - The nearly 400000 American patients on dialysis suffer high cardiovascular and infectious mortality, but there is now evidence that this morbid phenotype can be rescued by intensive dialytic therapy. Self-care dialysis at home is limited by patient fears about skill and safety. An implanted artificial kidney would provide the benefits of intensive therapy while avoiding the focal points of patient concern. Hollow fiber polymer membranes and dialytic waste removal are lifesaving innovations but are difficult to adapt to implantable therapies. Biomimetic membranes and living cells can replicate the native kidney's strategy for waste removal. Three key technology developments are necessary for implementation of an implantable artificial kidney: high efficiency ultrafiltration membranes, control of blood-materials interactions such as thrombosis and fouling, and stable differentiated function of renal proximal tubule cells in an engineered construct. There has been significant progress in demonstrating proof-of-concept experiments in each key technology area.

UR - http://www.scopus.com/inward/record.url?scp=80054744814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054744814&partnerID=8YFLogxK

M3 - Article

C2 - 21775942

AN - SCOPUS:80054744814

VL - 53

SP - 155

EP - 166

JO - Panminerva Medica

JF - Panminerva Medica

SN - 0031-0808

IS - 3

ER -

Roy S, Goldman KG, Marchant RE, Zydney A, Brown DL, Fleischman AJ et al. Implanted renal replacement for end-stage renal disease. Panminerva Medica. 2011 Sep 1;53(3):155-166.